Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
1351 Rifampicin 300mg Capsule J04AB02-000-C10-02-XXX B i) Tuberculosis
ii) Leprosy
iii) Prophylaxis for meningococcal meningitis
iv)Staphylococcus biofilm related prosthetic joint infection or any biofilm sensitive to rifampicin in combination therapy with another antibiotic		 None i) ADULT: 450 - 600 mg as a single morning dose.
CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg
ii) ADULT: 600 mg/day
CHILD: 10mg/kg
iii) ADULT: 600 mg twice daily for 2 days
CHILD: 10mg/kg twice daily for 2 days
INFANT: 5mg/kg twice daily for 2 days
iv) ADULT: 600mg OD
CHILD: 10-20mg/kg/day in 1-2 divided doses

Dosing is individualised and according to product insert/protocol.
1352 Rifampicin, Dapsone & Clofazimine J04AM02-961-T99-01-XXX B For the treatment of leprosy and tuberculosis None Rifampicin: 600 mg once monthly, Dapsone: 100 mg daily, Clofazimine: 300 mg once monthly and 50 mg daily (or 100 mg on alternate days)
1353 Ringers Solution (contained sodium chloride, potassium chloride and calcium chloride) B05XA30-905-P60-01-XXX B As a source of electrolytes and water for hydration/replenishing of chloride None According to the needs of the patient
1354 Risankizumab 150mg Solution for Injection L04AC18-000-P50-02-XXX A* Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy with major involvement of special site (face, scalp, genitals, palmoplantar) - As third-line therapy (after failing/intolerant/contraindicated to standard systemic drugs and/or phototherapy and/or IL-17 inhibitors)
- To be prescribed by Dermatologists only		 150 mg administered by subcutaneous injection at week 0, week 4, and every 12 weeks thereafter.
Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment.
1355 Risperidone 1 mg Tablet N05AX08000T1001XX B i) Schizophrenia, including first episode psychosis, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions

ii) Short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation.		 i) ADULT:
Initial dose: 2 mg/day.
Maintenance dose: 4 to 6 mg. Max: 16mg/day
CHILD: Not recommended
ELDERLY:
Initial dose: 0.5 mg twice daily.
Maintenance: 1 to 2 mg twice daily.

ii) CHILD & ADOLESCENTS, 5-18 years
≥ 50 kg: Initial - 0.5 mg once daily Optimum dose: 1mg once daily
< 50 kg: Initial - 0.25 mg once daily Optimum dose: 0.5mg once daily

Dosing should be individualized according to product insert.
1356 Risperidone 1 mg/ml Oral Solution N05AX08000L5001XX A i) Schizophrenia, including first episode psychosis, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions

ii) Short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation.		 i) ADULT:
Initial dose: 2 mg/day.
Maintenance dose: 4 to 6 mg. Max: 16mg/day
CHILD: Not recommended
ELDERLY:
Initial dose: 0.5 mg twice daily.
Maintenance: 1 to 2 mg twice daily.

ii) CHILD & ADOLESCENTS, 5-18 years
≥ 50 kg: Initial - 0.5 mg once daily Optimum dose: 1mg once daily
< 50 kg: Initial - 0.25 mg once daily Optimum dose: 0.5mg once daily

Dosing should be individualized according to product insert.
1357 Risperidone 2 mg Tablet N05AX08000T1002XX B Schizophrenia ADULT:
Initial dose: 2 mg/day.
Maintenance dose: 4 to 6 mg. Max: 16mg/day
CHILD: Not recommended
ELDERLY:
Initial dose: 0.5 mg twice daily.
Maintenance: 1 to 2 mg twice daily.

Dosing should be individualized according to product insert.
1358 Risperidone 25 mg Injection (Long Acting) N05AX08000P3001XX A* Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia 25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
1359 Risperidone 37.5 mg Injection (Long Acting) N05AX08000P3002XX A* Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia 25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
1360 Risperidone 50 mg Injection (Long Acting) N05AX08000P3003XX A* Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia 25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
1361 Ritonavir 100mg Capsule J05AE03-000-C10-01-XXX A* Progressive or advanced HIV infection in combination with other antiretroviral agents. Criteria for use:
a) Clinical AIDS
b) CD4 less than 350 cells or
c) Viral load more than 10,000 copies/ml		 ADULT: (Single PI) initially 300 mg twice daily, increase by 100 mg twice daily increments to 600 mg twice daily. (Dual PI) Initially 200mg BD, then increase by 100mg BD & reaching 400mg BD within 2 wk.
1362 Ritonavir 80mg/ml Solution J05AE03-000-L99-01-XXX A* Progressive or advanced HIV infection in combination with other antiretroviral agents. Criteria for use:
a) Clinical AIDS
b) CD4 less than 350 cells or
c) Viral load more than 10,000 copies/ml		 ADULT: 400 - 600 mg twice daily. CHILD: >1 month, initiate at dise of 25mg/m2 twice daily, titrate dose upward every 2-3 days by 50mg/m2 twice daily (maximum dose 600mg twice daily)
1363 Rituximab 10mg/ml Injection L01XC02000P3001XX A* i) Treatment of patients with relapsed or chemo-resistant low grade or follicular B-cell Non-Hodgkin's lymphoma
ii) Adjunctive therapy with combination chemoagents for aggressive Non-Hodgkin Lymphoma
iii) Severe active rheumatoid arthritis with inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARDs) including one or more tumour necrosis factor (TNF) inhibitor therapies
iv) Maintenance in relapsed/ refractory follicular lymphoma after response to induction therapy		 i) 375 mg/m2 BSA administered as an IV infusion through a dedicated line once weekly for 4 weeks
ii) Combination with CHOP (cyclophosphamide, doxorubicin, prednisone and vincristine) as 375 mg/m2 BSA on day 1 of each chemotherapy cycle for 8 cycles after IV administration of the glucocorticoid component of CHOP.
iii) 1000 mg IV infusion followed by a second 1000 mg IV infusion two weeks later
iv) 375mg/m2 BSA once every 3 months until disease progression or for a maximum period of two years.
1364 Rituximab 1400mg/11.7ml solution for subcutaneous injection L01XC02-000-P30-04-XXX A* i) Treatment of patients with relapsed or chemo-resistant low grade or follicular B-cell Non-Hodgkin's lymphoma;
ii) Adjunctive therapy with combination chemo-agents for aggressive Non-Hodgkin Lymphoma;
iii) Maintenance in relapsed/ refractory follicular lymphoma after response to induction therapy.		 i) As monotherapy, first cycle with rituximab (IV formulation) 375mg/m2 administered as an intravenous infusion, followed by subsequent cycles with rituximab SC at a fixed dose of 1400mg per cycle, once weekly. In total: 4 weeks.
ii) Combination with CHOP (cyclophosphamide, doxorubicin, prednisone and vincristine): first dose with rituximab (IV formulation) 375 mg/m2 administered as an intravenous infusion followed by subsequent cycles with rituximab SC injected at a fixed dose of 1400mg per cycle. In total: for up to 8 cycles. Rituximab should be administered on day 1 of each chemotherapy cycle after IV administration of the glucocorticoid component of CHOP.
iii) 1400mg SC once every 3 months until disease progression or for a maximum period of two years.

Note:
• Premedication consisting of an anti-pyretic, antihistamine (e.g. paracetamol and diphenhydramine) and glucocorticoids, before each administration of rituximab.
• All patients must always receive their first dose of rituximab by intravenous administration (using intravenous formulation) at a dose of 375mg/m2 body surface area. The subcutaneous formulation of 1400mg should only be given at the second or subsequent cycles.
• Patients who were not able to receive the full rituximab intravenous infusion dose should continue to receive subsequent cycles with rituximab IV doses.
• Subcutaneous formulation is not intended for intravenous administration and should be given via subcutaneous injection only. The 1400 mg strength is intended for subcutaneous use in non-Hodgkin lymphoma (NHL) only.
1365 Rivaroxaban 10 mg Tablet B01AX06000T1001XX A* i. Prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery
ii. Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults
iii. Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults		 None Indication i:
10 mg once daily. Initial dose should be taken 6 to 10 hour post-surgery provided that haemostasis has been established. Duration of treatment: Major hip surgery 5 weeks. Major knee surgery 2 weeks

Indication ii & iii
15mg BD for 21 days, followed by 20mg OD
Dose reduction to 15mg OD for renal impairment (CrCl 15 to 49 ml/min)
1366 Rivaroxaban 15 mg Tablet B01AX06000T1002XX A* i) Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ 75 yrs, diabetes mellitus, prior stroke or transient ischaemic attack.
ii)Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.
iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults.		 i) 20mg once daily or 15mg once daily (CrCl 15 – 49 ml/min)
ii) & (iii) 15mg BD for 21 days, followed by 20mg OD
1367 Rivaroxaban 20 mg Tablet B01AX06000T1003XX A* i)Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ 75 yrs, diabetes mellitus, prior stroke or transient ischaemic attack.
ii)Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.
iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults.		 i) 20mg once daily or 15mg once daily (CrCl 15 – 49 ml/min)
ii) & (iii) 15mg BD for 21 days, followed by 20mg OD
1368 Rivastigmine 1.5mg Capsule N06DA03123C1001XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily.
If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1369 Rivastigmine 13.3mg/24hr Transdermal Patch N03DA03123M7003XX A* i) Mild to moderately severe dementia of the Alzheimer's type
ii) Severe dementia of the Alzheimer's type
iii) Mild to moderately severe dementia associated with Parkinson's disease		 Use as second line/alternative option if the first line medication with oral tablet failed or patients are not able to tolerate the oral medication. Initial: 4.6mg/24hr once daily
Maintenance: 9.5mg/24hr once daily after a minimum of 4 weeks and then 13.3mg/24hr if tolerated

Dosing is individualised and according to product insert.
1370 Rivastigmine 2 mg/ml Oral Solution N06DA03123L9901XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily. May be increased after a minimum of 2 weeks of treatment to 3 mg 2 times daily. Subsequently to 4.5 mg 2 times daily, up to maximum of 6 mg 2 times daily.
If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1371 Rivastigmine 3mg Capsule N06DA03123C1002XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1372 Rivastigmine 4.5 mg Capsule N06DA03123C1003XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily.
If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1373 Rivastigmine 4.6mg/24hr Transdermal Patch N06DA03123M7001XX A* i) Mild to moderately severe dementia of the Alzheimer's type
ii) Severe dementia of the Alzheimer's type
iii) Mild to moderately severe dementia associated with Parkinson's disease		 Use as second line/alternative option if the first line medication with oral tablet failed or patients are not able to tolerate the oral medication Initial: 4.6mg/24hr once daily
Maintenance: 9.5mg/24hr once daily after a minimum of 4 weeks and then 13.3mg/24hr if tolerated

Dosing is individualised and according to product insert.
1374 Rivastigmine 6 mg Capsule N06DA03123C1004XX A* Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily.
If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1375 Rivastigmine 9.5 mg/24hr Transdermal Patch N06DA03123M7002XX A* i) Mild to moderately severe dementia of the Alzheimer's type
ii) Severe dementia of the Alzheimer's type
iii) Mild to moderately severe dementia associated with Parkinson's disease		 Use as second line/alternative option if the first line medication with oral tablet failed or patients are not able to tolerate the oral medication Initial: 4.6mg/24hr once daily
Maintenance: 9.5mg/24hr once daily after a minimum of 4 weeks and then 13.3mg/24hr if tolerated

Dosing is individualised and according to product insert.
1376 Rocuronium Bromide 10mg/ml Injection M03AC09-320-P30-01-XXX A* As an adjunct to general anaesthesia to facilitate endotracheal intubation, to provide skeletal muscle relaxation during surgery and to facilitate mechanical ventilation in adults, children and infants from one month of age. None Adult: Initial: 0.6mg/kg. Higher doses of 1 mg/kg may be used for intubation during rapid sequence induction of anaesthesia. Maintenance: 0.15mg/kg (may reduce to 0.075-0.1 mg/kg if inhalational anaesthesia is used) or by infusion at a rate of 0.3-0.6mg/kg/hr (0.3-0.4mg/kg/hr if inhalational anaesthesia is used). Doses should be based on ideal body weight for obese patients weighing >30% above the ideal body weight.

Child: Infants and children >1 mth: Initially: 0.6mg/kg. Maintenance: 0.15mg/kg or by infusion at a rate of 0.3-0.6mg/kg/hr, maintenance doses may be required more frequently than in adult patients. Elderly/patients with hepatic and/or biliary tract disease and/or renal impairment: Initially: 0.6mg/kg. Maintenance: 0.075-0.1 mg/kg or by infusion at a rate of 0.3-0.4mg/kg/hr.
1377 Ropinirole HCI 2 mg Extended Release Tablet N04BC04110T5003XX A* Treatment of idiopathic Parkinson?s disease. It may be used as monotherapy or in combination with levodopa ADULT: Initially 2 mg once daily for the 1st week. May be increased by 2 mg at ≥1 week intervals. Max: 24 mg/day. Switching from ropinirole immediate-realease to prolonged-release tablet; dose of ropinirole prolonged release tablet should be based on the total daily dose of ropinirole immediate-release tab the patient was taking. Tablets should be taken at a similar time each day with or without food, must be swallowed whole and must not be chewed, crushed or divided.
1378 Ropinirole HCI 4 mg Extended Release Tablet N04BC04110T5004XX A* Treatment of idiopathic Parkinson?s disease. It may be used as monotherapy or in combination with levodopa ADULT: Initially 2 mg once daily for the 1st week. May be increased by 2 mg at ≥1 week intervals. Max: 24 mg/day. Switching from ropinirole immediate-realease to prolonged-release tablet; dose of ropinirole prolonged release tablet should be based on the total daily dose of ropinirole immediate-release tab the patient was taking. Tablets should be taken at a similar time each day with or without food, must be swallowed whole and must not be chewed, crushed or divided.
1379 Ropinirole HCl 0.25 mg Tablet N04BCO4-110-T10-01-XXX A* i) Treatment of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa
ii) Treatment of restless leg syndrome		 i) 0.25 mg 3 times daily gradually increasing till adequate response obtained up to a maximum of 24 mg/day. Most patients need 3-9 mg/day
ii) Initial: 0.25mg ON for 2 days then increased if tolerated to 0.5mg ON. Further dose increment of 0.5mg/week can be made until optimal response is achieved
1380 Ropinirole HCl 1 mg Tablet N04BCO4-110-T10-02-XXX A* i) Treatment of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa
ii) Treatment of restless leg syndrome		 i) 0.25 mg 3 times daily gradually increasing till adequate response obtained up to a maximum of 24 mg/day. Most patients need 3-9 mg/day
ii) Initial: 0.25mg ON for 2 days then increased if tolerated to 0.5mg ON. Further dose increment of 0.5mg/week can be made until optimal response is achieved

Pages